EdgeOne Medical strengthens its regulatory and combination product expertise by appointing industry veteran Lee Leichter as Senior Advisor.
EdgeOne Medical, an integrated development partner specializing in drug-device combination products, has announced that industry veteran Lee Leichter will join the organization as a Senior Advisor. The collaboration brings together EdgeOne Medical’s technical development expertise with Leichter’s decades-long experience in regulatory strategy, engineering, and global standards development, strengthening the company’s ability to guide pharmaceutical and medical technology companies through the increasingly complex landscape of combination product development.
Drug-device combination products represent one of the most rapidly evolving areas in the life sciences industry. These products integrate pharmaceutical therapies with specialized delivery devices to enhance treatment effectiveness, improve patient compliance, and enable innovative therapeutic approaches. However, combining drug formulations with medical devices introduces significant technical and regulatory challenges. Developers must manage pharmaceutical formulation science, mechanical and electronic device engineering, regulatory compliance, quality systems, human factors considerations, and lifecycle management—all within a single integrated product.
As the demand for advanced drug delivery solutions continues to grow, the complexity of these products has also increased. Pharmaceutical and biotechnology companies are developing increasingly sophisticated delivery systems such as autoinjectors, wearable injectors, inhalation devices, and implantable technologies that must meet strict global regulatory requirements. Navigating this environment requires deep cross-disciplinary expertise, making strategic guidance from experienced industry leaders increasingly valuable.
Leichter has long been recognized as one of the pioneers in the combination product field. Over the course of his career, he has helped pharmaceutical, biotechnology, and medical device companies address the technical and regulatory challenges associated with bringing complex drug-device systems to market. His work has focused on aligning engineering realities with regulatory expectations while supporting organizations in the development, validation, and commercialization of advanced drug delivery technologies.
Throughout his professional journey, Leichter has contributed to a wide range of combination product platforms. His experience spans autoinjectors designed for self-administration, wearable drug delivery systems that allow continuous or timed dosing, inhalation devices used in respiratory therapies, and other specialized drug delivery mechanisms. Each of these technologies requires careful integration between the therapeutic compound and the mechanical or electronic system that administers it. Achieving this integration involves not only design and engineering expertise but also deep knowledge of regulatory frameworks and risk management practices.
Beyond direct product development, Leichter’s experience also extends into regulatory strategy and lifecycle management. He has advised companies on how to design combination products that meet the expectations of global regulatory agencies while maintaining manufacturability and long-term product reliability. This includes guidance on device usability studies, risk analysis, product verification and validation, and regulatory documentation required for product approvals across different international markets.
Leichter’s expertise is also reflected in his longstanding involvement in several influential industry organizations that shape standards and best practices for combination products and medical technologies. Over the years, he has contributed to the development of industry guidance and technical frameworks through participation in groups such as the Parenteral Drug Association, International Organization for Standardization, Association for the Advancement of Medical Instrumentation, Combination Product Coalition, Human Factors and Ergonomics Society, and the Regulatory Affairs Professionals Society.
Through these organizations, he has contributed to the advancement of technical standards, regulatory discussions, and professional education within the global life sciences community. His work has helped bridge the gap between device engineering, regulatory science, and pharmaceutical development, providing guidance that supports safer, more effective drug-device products.
In his new role as Senior Advisor to EdgeOne Medical, Leichter will collaborate closely with the company’s leadership and technical teams. His responsibilities will include providing insights into evolving regulatory expectations for combination products, identifying emerging industry trends, and helping the organization stay aligned with new technical standards and regulatory guidance. By contributing this strategic perspective, Leichter will support EdgeOne Medical’s ongoing efforts to strengthen its service offerings and provide clients with advanced development support.
EdgeOne Medical has established itself as a partner for pharmaceutical and biotechnology companies seeking to develop integrated drug-device products. The company works with organizations at various stages of development, from early feasibility and device design through regulatory submission and commercialization. By combining expertise in engineering, quality systems, and regulatory compliance, EdgeOne helps clients address the challenges associated with bringing innovative combination therapies to market.
According to EdgeOne Medical’s leadership, Leichter’s involvement will further enhance the company’s ability to support clients operating in this complex field. Lilli Zakarija, CEO of EdgeOne Medical, emphasized the significance of adding such a respected industry figure to the organization’s advisory network. She noted that Leichter’s experience across regulatory strategy, engineering realities, and global standards development provides a valuable perspective that will benefit both the company’s internal teams and its clients.
“Lee is one of the most respected experts in the combination product field,” Zakarija said. “His experience across regulatory strategy, engineering realities, and global standards development is incredibly valuable for our team. We are thrilled to have him working alongside EdgeOne as we continue to help companies navigate the growing complexity of drug-device development.”
Leichter also expressed enthusiasm about joining EdgeOne Medical as a Senior Advisor. He noted that the combination product landscape continues to evolve rapidly as pharmaceutical therapies become more advanced and delivery technologies grow increasingly sophisticated. According to Leichter, companies must continually adapt to new regulatory expectations and technical challenges while ensuring that products remain safe, reliable, and user-friendly for patients.
“Combination products continue to evolve as therapies become more advanced and delivery technologies grow more sophisticated,” Leichter said. “EdgeOne has built a strong reputation for technical depth and collaborative problem solving, and I look forward to supporting the team as they continue helping companies address the challenges of modern drug-device development.”
As the life sciences industry continues to prioritize patient-centric therapies and innovative drug delivery solutions, the role of experienced advisors and collaborative development partners is becoming increasingly important. By bringing together engineering expertise, regulatory insight, and industry leadership, EdgeOne Medical aims to help pharmaceutical and medical technology companies successfully translate complex scientific innovations into practical healthcare solutions.
The addition of Lee Leichter as Senior Advisor represents another step in EdgeOne Medical’s ongoing effort to strengthen its capabilities and expand its influence within the combination product ecosystem. With growing global demand for advanced drug-device technologies, partnerships like this are expected to play a critical role in shaping the next generation of therapeutic delivery systems and improving outcomes for patients worldwide.